Skip to main content
Top
Published in: AIDS Research and Therapy 1/2005

Open Access 01-12-2005 | Research

Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection

Authors: Magnus Gisslén, Lars Rosengren, Lars Hagberg, Steven G Deeks, Richard W Price

Published in: AIDS Research and Therapy | Issue 1/2005

Login to get access

Abstract

Background

The neurofilament is a major structural component of myelinated axons. Increased cerebrospinal fluid (CSF) concentrations of the light chain of the neurofilament protein (NFL) can serve as a sensitive indicator of central nervous system (CNS) injury. To assess whether interrupting antiretroviral treatment of HIV infection might have a deleterious effect on the CNS, we measured NFL levels in HIV-infected subjects interrupting therapy.
We identified subjects who had CSF HIV RNA concentrations below 50 copies/mL at the time combination antiretroviral therapy was interrupted, and for whom CSF samples were available before and after the interruption.

Results

A total of 8 subjects were studied. The median (range) CSF NFL level at baseline was <125 (<125–220) ng/L (normal <250 ng/L). All 8 subjects exhibited an increase in CSF and plasma HIV RNA after stopping therapy, accompanied by intrathecal immunoactivation as evidenced by CSF lymphocytic pleocytosis (7/8 patients) and increased CSF neopterin concentration (5/6 patients). Three subjects showed a consistent increase in CSF NFL, rising from <125 ng/L to a maximum of 880 (at day 148), 1,010 (day 58) and 10,930 ng/L (day 101). None exhibited new neurological symptoms or signs, or experienced functional deterioration during the period off treatment; of 5 who underwent brief quantitative neurological testing, none showed worsening performance.

Conclusion

These findings suggest that resurgence of active HIV replication may result in measurable, albeit subclinical, CNS injury. Further studies are needed to define the frequency and pathobiological importance of the increase in CSF NFL.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003, 362 (9377): 22-29. 10.1016/S0140-6736(03)13802-0CrossRefPubMed Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003, 362 (9377): 22-29. 10.1016/S0140-6736(03)13802-0CrossRefPubMed
2.
go back to reference d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J: Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004, 55 (3): 320-328. 10.1002/ana.10827CrossRefPubMed d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J: Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004, 55 (3): 320-328. 10.1002/ana.10827CrossRefPubMed
3.
go back to reference Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet. 2000, 356 (9239): 1423-1430. 10.1016/S0140-6736(00)02854-3CrossRefPubMed Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet. 2000, 356 (9239): 1423-1430. 10.1016/S0140-6736(00)02854-3CrossRefPubMed
4.
go back to reference Lori F, Lisziewicz J: Structured treatment interruptions for the management of HIV infection. Jama. 2001, 286 (23): 2981-2987. 10.1001/jama.286.23.2981CrossRefPubMed Lori F, Lisziewicz J: Structured treatment interruptions for the management of HIV infection. Jama. 2001, 286 (23): 2981-2987. 10.1001/jama.286.23.2981CrossRefPubMed
5.
go back to reference Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996, 67: 2013-2018.CrossRefPubMed Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996, 67: 2013-2018.CrossRefPubMed
6.
go back to reference Norgren N, Rosengren L, Stigbrand T: Elevated neurofilament levels in neurological diseases. Brain Res. 2003, 987 (1): 25-31. 10.1016/S0006-8993(03)03219-0CrossRefPubMed Norgren N, Rosengren L, Stigbrand T: Elevated neurofilament levels in neurological diseases. Brain Res. 2003, 987 (1): 25-31. 10.1016/S0006-8993(03)03219-0CrossRefPubMed
7.
go back to reference Blennow M, Savman K, Ilves P, Thoresen M, Rosengren L: Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr. 2001, 90 (10): 1171-1175. 10.1080/080352501317061594CrossRefPubMed Blennow M, Savman K, Ilves P, Thoresen M, Rosengren L: Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr. 2001, 90 (10): 1171-1175. 10.1080/080352501317061594CrossRefPubMed
8.
go back to reference Rosen H, Karlsson JE, Rosengren L: CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J Neurol Sci. 2004, 221 (1-2): 19-24. 10.1016/j.jns.2004.03.003CrossRefPubMed Rosen H, Karlsson JE, Rosengren L: CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J Neurol Sci. 2004, 221 (1-2): 19-24. 10.1016/j.jns.2004.03.003CrossRefPubMed
9.
go back to reference Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M: Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004, 63 (9): 1586-1590.CrossRefPubMed Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M: Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004, 63 (9): 1586-1590.CrossRefPubMed
10.
go back to reference Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J: Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003, 61 (12): 1720-1725.CrossRefPubMed Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J: Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003, 61 (12): 1720-1725.CrossRefPubMed
11.
go back to reference Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A: Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999, 52 (5): 1090-1093.CrossRefPubMed Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A: Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999, 52 (5): 1090-1093.CrossRefPubMed
12.
go back to reference Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A: Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001, 66 (3): 510-516. 10.1002/jnr.1242CrossRefPubMed Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A: Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001, 66 (3): 510-516. 10.1002/jnr.1242CrossRefPubMed
13.
go back to reference Van Geel WJ, Rosengren LE, Verbeek MM: An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods. 2005, 296 (1-2): 179-185. 10.1016/j.jim.2004.11.015CrossRefPubMed Van Geel WJ, Rosengren LE, Verbeek MM: An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods. 2005, 296 (1-2): 179-185. 10.1016/j.jim.2004.11.015CrossRefPubMed
14.
go back to reference Norgren N, Karlsson JE, Rosengren L, Stigbrand T: Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics. 2002, 21 (1): 53-59. 10.1089/15368590252917647CrossRefPubMed Norgren N, Karlsson JE, Rosengren L, Stigbrand T: Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics. 2002, 21 (1): 53-59. 10.1089/15368590252917647CrossRefPubMed
15.
go back to reference Hagberg L, Fuchs D, Rosengren L, Gisslen M: Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol. 2000, 102: 51-55. 10.1016/S0165-5728(99)00150-2CrossRefPubMed Hagberg L, Fuchs D, Rosengren L, Gisslen M: Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol. 2000, 102: 51-55. 10.1016/S0165-5728(99)00150-2CrossRefPubMed
16.
go back to reference Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG: Cerebrospinal fluid response to structured treatment interruption after virological failure. Aids. 2001, 15 (10): 1251-1259. 10.1097/00002030-200107060-00006CrossRefPubMed Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG: Cerebrospinal fluid response to structured treatment interruption after virological failure. Aids. 2001, 15 (10): 1251-1259. 10.1097/00002030-200107060-00006CrossRefPubMed
17.
go back to reference Price RW, Deeks SG: Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. J Neurovirol. 2004, 10 Suppl 1: 44-51. 10.1080/13550280490268223CrossRefPubMed Price RW, Deeks SG: Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. J Neurovirol. 2004, 10 Suppl 1: 44-51. 10.1080/13550280490268223CrossRefPubMed
18.
go back to reference Hagberg L, Andersson LM, Abdulle S, Gisslen M: Clinical application of cerebrospinal fluid neopterin concentrations in HIV infection. Pteridines. 2004, 15: 102-106.CrossRef Hagberg L, Andersson LM, Abdulle S, Gisslen M: Clinical application of cerebrospinal fluid neopterin concentrations in HIV infection. Pteridines. 2004, 15: 102-106.CrossRef
19.
go back to reference Tibbling G, Link H, Öhman S: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977, 37: 385-390.CrossRefPubMed Tibbling G, Link H, Öhman S: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977, 37: 385-390.CrossRefPubMed
20.
go back to reference Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K: Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. Aids. 1999, 13 (13): 1677-1685. 10.1097/00002030-199909100-00011CrossRefPubMed Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K: Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. Aids. 1999, 13 (13): 1677-1685. 10.1097/00002030-199909100-00011CrossRefPubMed
21.
go back to reference Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD: Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003, 349 (9): 837-846. 10.1056/NEJMoa035103CrossRefPubMed Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD: Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003, 349 (9): 837-846. 10.1056/NEJMoa035103CrossRefPubMed
22.
go back to reference Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL: Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A. 1987, 84 (10): 3472-3476.PubMedCentralCrossRefPubMed Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL: Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A. 1987, 84 (10): 3472-3476.PubMedCentralCrossRefPubMed
23.
go back to reference Fischer M, Hafner R, Schneider C, Trkola A, Joos B, Joller H, Hirschel B, Weber R, Gunthard HF: HIV RNA in plasma rebounds within days during structured treatment interruptions. Aids. 2003, 17 (2): 195-199. 10.1097/00002030-200301240-00009CrossRefPubMed Fischer M, Hafner R, Schneider C, Trkola A, Joos B, Joller H, Hirschel B, Weber R, Gunthard HF: HIV RNA in plasma rebounds within days during structured treatment interruptions. Aids. 2003, 17 (2): 195-199. 10.1097/00002030-200301240-00009CrossRefPubMed
24.
go back to reference Huber C, Batchelor R, Fuchs D, Hause A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984, 160: 310-316. 10.1084/jem.160.1.310CrossRefPubMed Huber C, Batchelor R, Fuchs D, Hause A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984, 160: 310-316. 10.1084/jem.160.1.310CrossRefPubMed
25.
go back to reference Brew BJ, Dunbar N, Pemberton L, Kaldor J: Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis. 1996, 174: 294-298.CrossRefPubMed Brew BJ, Dunbar N, Pemberton L, Kaldor J: Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis. 1996, 174: 294-298.CrossRefPubMed
26.
go back to reference Gisslen M, Fuchs D, Svennerholm B, Hagberg L: Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999, 21 (4): 271-276.CrossRefPubMed Gisslen M, Fuchs D, Svennerholm B, Hagberg L: Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999, 21 (4): 271-276.CrossRefPubMed
28.
go back to reference Studahl M, Rosengren L, Gunther G, Hagberg L: Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol. 2000, 247 (8): 636-642. 10.1007/s004150070134CrossRefPubMed Studahl M, Rosengren L, Gunther G, Hagberg L: Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol. 2000, 247 (8): 636-642. 10.1007/s004150070134CrossRefPubMed
Metadata
Title
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection
Authors
Magnus Gisslén
Lars Rosengren
Lars Hagberg
Steven G Deeks
Richard W Price
Publication date
01-12-2005
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2005
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-2-6

Other articles of this Issue 1/2005

AIDS Research and Therapy 1/2005 Go to the issue